us clinical guidance

Chronic noncancer pain assessment and safer treatment

US person-centered chronic-pain evaluation, multimodal nonopioid care and flexible CDC/VA-DoD opioid safety principles.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Outpatients aged 18 years or older with pain lasting more than three months, excluding pain related to sickle cell disease, active cancer treatment, palliative care or end-of-life care from the CDC opioid-guideline scope.

The Bottom Line

  • Validate the patient’s pain and define mechanisms, contributors, function and goals without requiring a single structural lesion to justify care or assuming that pain intensity alone determines treatment.
  • Build a multimodal plan around condition-specific nonpharmacologic and nonopioid pharmacologic treatments, sleep, mood, movement and social barriers, measuring function as well as symptom change.
  • Prefer nonopioid therapies for chronic pain and consider starting an opioid only when expected benefits for pain and function are likely to outweigh risks after an informed, individualized discussion.
  • For established opioid therapy, review benefit and harm collaboratively and avoid rigid thresholds, abrupt discontinuation, rapid forced taper or dismissal from care.

Practical clinical workflow

1
Characterize location, quality, neurologic features, trajectory, prior injury or disease, sleep, mood, trauma, substances, current medicines, work, caregiving and meaningful activities the patient wants to regain.
2
Examine for a coherent pain mechanism and urgent disease, review prior records and tests and avoid repeating imaging when it will not change management or explain function.
3
Agree on staged treatments and measurable functional goals, choosing physical, behavioral, interventional and medication options according to diagnosis, evidence, access and patient preference.
4
If opioids are used, review state prescription data where applicable, toxicology when clinically useful, concurrent sedatives, naloxone need, treatment response and signs of opioid-use disorder at planned follow-up.

Safety boundaries and escalation

  • New motor or sphincter deficit, fever, cancer red flags, fracture risk, acute vascular symptoms, rapidly progressive neurologic change or suicidal crisis requires urgent diagnostic assessment rather than routine pain escalation.
  • Opioids combined with benzodiazepines, alcohol or other sedatives increase overdose risk; offer naloxone when risk factors are present and provide overdose education.
  • When opioid-use disorder is identified, offer or arrange evidence-based medication treatment; do not abandon pain care or use punitive discharge as a safety strategy.
  • A taper can cause withdrawal, distress and destabilization when too rapid; unless there is a life-threatening issue, plan changes collaboratively, monitor closely and maintain access to care.

Localization

CDC 2022 is voluntary guidance, not a law or inflexible dose policy, and explicitly excludes cancer, sickle cell, palliative and end-of-life pain. State controlled-substance law, prescription-monitoring requirements, Medicaid and insurer rules vary.

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionCDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022MMWR 71(3); DOI 10.15585/mmwr.rr7103a1 · published 2022-11-04 · accessed 2026-08-20
    view source
  2. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for the Use of Opioids in the Management of Chronic PainVersion 4.0 (2022) · published 2022-05-01 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.